Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Regulation

Ultrarare inflection point: stakeholders argue for biomarker-based approvals

Reagan-Udall Foundation meeting on biomarkers could change FDA policy on neuronal MPS endpoints, unleash approvals

February 29, 2024 1:34 AM UTC

A meeting convened by the Reagan-Udall Foundation for the FDA on qualifying rare disease biomarkers for accelerated approvals could be an inflection point for patients with ultrarare diseases, their families, biotech companies, and FDA.

The workshop, held on Feb. 21, focused on the use of heparan sulfate measured in cerebrospinal fluid (CSF) to support approval of treatments for neuronal mucopolysaccharidoses (MPS), a set of related ultrarare disorders.  ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article